@itsjustgracenow's HRT personalization claim, fact-checked

What did @itsjustgracenow actually say?

She got this one mostly right from the jump. The creator shared her own feminizing HRT journey, explaining she started on estradiol alone for six months before adding progesterone, and never used an anti-androgen like spironolactone. Her core message: "it's not gonna work for other people" and "always make sure to ask your doctor instead of asking people on TikTok." That's a responsible framing you don't see enough in this corner of the internet.

She was responding to a comment, making the point that comparing your protocol to someone else's is a dead end. She didn't push a specific dosage, didn't recommend her regimen, and explicitly said her year-plus of experience still doesn't qualify her to tell others what to take. That's a level of epistemic humility that a lot of medical influencers with actual credentials fail to demonstrate.

Does the science back this up?

Yes, firmly. Individual variation in hormone response is one of the better-documented realities in transgender medicine. The evidence is not subtle about this.

A 2021 review by Cheung et al. in the Journal of Clinical Endocrinology and Metabolism confirmed significant inter-individual variability in estradiol levels even at equivalent doses, driven by differences in cytochrome P450 enzyme activity, route of administration, and baseline hormone levels. This is why two people on identical oral estradiol doses can end up with serum estradiol levels that differ by a factor of three or more.

The role of anti-androgens is equally variable. Spironolactone, cyproterone acetate, and GnRH agonists are all used to suppress endogenous testosterone in transfeminine patients, but their side effect profiles and efficacy differ substantially by individual. Some patients achieve adequate suppression through high-dose estradiol monotherapy alone, which is consistent with what the creator describes. A 2019 observational study by Angus et al. in Endocrinology documented that a subset of transfeminine patients on estradiol monotherapy reached testosterone suppression within the female reference range without any additional anti-androgen. So her personal experience is biologically plausible, not just anecdote.

What did they get wrong (or right)?

Mostly right, with one gap worth naming. She never addressed why protocols differ, only that they do. That's fine for a short video, but it leaves viewers without any framework for understanding what drives those differences.

The practical reality is that route of administration matters enormously. Oral estradiol has lower bioavailability and higher hepatic first-pass metabolism compared to transdermal or injectable forms. Subcutaneous versus intramuscular injection affects peak and trough levels. Body composition, gut microbiome, and liver enzyme activity all modulate response. None of that is complicated to explain at a basic level, and it would have made her correct point more actionable.

Her mention of progesterone is worth a closer look. She frames it as a natural next step after estradiol, but the evidence base for progesterone in transfeminine HRT is genuinely thin. A 2020 commentary by Prior in Climacteric argued for its inclusion based on physiological reasoning, but randomized controlled trial data on outcomes like breast development or quality of life in this population is still lacking. Her experience is valid; the implied generalizability is shakier.

What should you actually know?

Feminizing HRT is not a fixed formula. Protocols are titrated based on lab values, symptom response, risk factors, and patient goals. The Endocrine Society's 2017 clinical practice guidelines, updated in part by Hembree et al. in JCEM, lay out target serum ranges rather than target doses precisely because dose-to-level relationships are unpredictable across individuals.

Anti-androgens are not universally required. Whether a patient needs spironolactone, a GnRH agonist, or nothing beyond estradiol depends on their baseline testosterone, their estradiol response, and their individual risk profile. Spironolactone, for instance, carries blood pressure and potassium risks that make it a poor default for everyone.

The creator's sign-off advice, "ask your doctor," is correct but incomplete for a lot of her audience. Access to informed-consent clinics and trans-competent providers is geographically and economically uneven. Pointing toward telehealth platforms that specialize in this area is a practical extension of that advice that she didn't make, but that's a gap in the content, not a factual error.

• Serum estradiol targets in transfeminine care are typically 100-200 pg/mL, per Hembree et al. 2017, but this is a general reference range, not a universal prescription.
• Route of administration changes pharmacokinetics significantly, which is why the same milligram dose can produce very different blood levels in different people.
• Progesterone's role in transfeminine HRT remains an area of active debate with limited RCT data.